FR2740339B1
(fr)
*
|
1995-10-26 |
1997-12-05 |
Oreal |
Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
|
US6369272B1
(en)
|
1997-01-13 |
2002-04-09 |
Glaxosmithkline |
Nitric oxide synthase inhibitors
|
US6620848B2
(en)
|
1997-01-13 |
2003-09-16 |
Smithkline Beecham Corporation |
Nitric oxide synthase inhibitors
|
JP2001511151A
(ja)
*
|
1997-02-04 |
2001-08-07 |
ザ ジェネラル ホスピタル コーポレイション |
表皮又は皮膚疾患部の処理方法と形質転換動物
|
AU8647198A
(en)
*
|
1997-08-12 |
1999-03-01 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for diseases associated with bone resorption
|
EE200000519A
(et)
*
|
1998-03-11 |
2002-02-15 |
G.D. Searle & Co. |
Lämmastikoksiidi süntaasi inhibiitoritena toimivad halogeenitud amidinoaminohappederivaadid
|
WO1999055679A1
(en)
|
1998-04-28 |
1999-11-04 |
Trega Biosciences, Inc. |
Isoquinoline compound melanocortin receptor ligands and methods of using same
|
US6284735B1
(en)
*
|
1998-04-28 |
2001-09-04 |
Lion Bioscience Ag |
HP-3228 and related peptides to treat sexual dysfunction
|
US6534503B1
(en)
|
1998-04-28 |
2003-03-18 |
Lion Bioscience Ag |
Melanocortin receptor-3 ligands to treat sexual dysfunction
|
GB9811599D0
(en)
|
1998-05-30 |
1998-07-29 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
WO2001005401A1
(en)
*
|
1999-07-16 |
2001-01-25 |
Trega Biosciences, Inc. |
Melanocortin receptor-3 ligands to treat sexual dysfunction
|
PT1265860E
(pt)
*
|
2000-03-24 |
2005-10-31 |
Pharmacia Corp |
Compostos amidino uteis como inibidores de sintase de oxido nitrico
|
AR034120A1
(es)
*
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
GB0031179D0
(en)
*
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
DE10111052A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
|
DE10111050A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
|
DE10111054A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
|
DE10111049A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
|
US7012098B2
(en)
*
|
2001-03-23 |
2006-03-14 |
Pharmacia Corporation |
Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
|
JP2005532321A
(ja)
*
|
2002-05-16 |
2005-10-27 |
ファルマシア コーポレーション |
呼吸器の疾患および状態の、選択的iNOS阻害剤とPDE阻害剤による治療方法、ならびにそのための組成物
|
GB0214147D0
(en)
*
|
2002-06-19 |
2002-07-31 |
Glaxo Group Ltd |
Formulations
|
MXPA05008674A
(es)
*
|
2003-03-11 |
2005-10-18 |
Pharmacia Corp |
Sal cristalina clorhidrato maleato de s-[2-[(1-iminoetil)amino]etil]-2-metil-l-cisteina.
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
ATE517908T1
(de)
|
2005-01-10 |
2011-08-15 |
Glaxo Group Ltd |
Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
|
PE20061351A1
(es)
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
|
PE20100741A1
(es)
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
TW200730498A
(en)
|
2005-12-20 |
2007-08-16 |
Glaxo Group Ltd |
Compounds
|
AU2007242851A1
(en)
|
2006-04-20 |
2007-11-01 |
Glaxo Group Limited |
Novel compounds
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
DK2046787T3
(da)
|
2006-08-01 |
2011-07-18 |
Glaxo Group Ltd |
Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
|
WO2008147445A2
(en)
*
|
2006-11-09 |
2008-12-04 |
University Of Maryland, Baltimore |
Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
|
AR065804A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
|
CN102137858B
(zh)
|
2008-05-23 |
2014-07-23 |
潘米拉制药有限责任公司 |
5-脂氧合酶-活化蛋白抑制剂
|
EP2280946B1
(en)
|
2008-06-05 |
2016-02-10 |
Glaxo Group Limited |
4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
|
EP2280959B1
(en)
|
2008-06-05 |
2012-04-04 |
Glaxo Group Limited |
4-amino-indazoles
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
EP2406255B1
(en)
|
2009-03-09 |
2015-04-29 |
Glaxo Group Limited |
4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
|
US8354539B2
(en)
|
2009-03-10 |
2013-01-15 |
Glaxo Group Limited |
Indole derivatives as IKK2 inhibitors
|
EP2408769A1
(en)
|
2009-03-17 |
2012-01-25 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
WO2010107957A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2408916A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2010226604A1
(en)
|
2009-03-19 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
|
JP2012521763A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子1(STAT1)遺伝子発現のRNA干渉媒介性阻害
|
JP2012521762A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害
|
JP2012521764A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害
|
EP2411516A1
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012521765A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた細胞内接着分子1(ICAM−1)遺伝子発現のRNA干渉媒介性阻害
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
TW201103892A
(en)
|
2009-04-24 |
2011-02-01 |
Glaxo Group Ltd |
Compounds
|
CA2759476C
(en)
|
2009-04-30 |
2018-10-09 |
Julie Nicole Hamblin |
Novel compounds
|
MX337575B
(es)
*
|
2009-10-09 |
2016-03-10 |
Zafgen Corp |
Compuestos de sulfona y métodos para lafabricación y uso de éstos.
|
EP2507223A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
WO2011067364A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Novel compounds
|
US20120238571A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Indazole derivatives as pi 3-kinase
|
EP3020393B1
(en)
|
2009-12-16 |
2020-10-07 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
US9326987B2
(en)
|
2010-09-08 |
2016-05-03 |
Glaxo Group Limited |
Indazole derivatives for use in the treatment of influenza virus infection
|
EP2614058B1
(en)
|
2010-09-08 |
2015-07-08 |
GlaxoSmithKline Intellectual Property Development Limited |
POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
WO2012052459A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
ES2532213T3
(es)
|
2010-10-21 |
2015-03-25 |
Glaxo Group Limited |
Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
US20140005188A1
(en)
|
2011-03-11 |
2014-01-02 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
WO2015042078A2
(en)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
US9399637B2
(en)
|
2014-03-28 |
2016-07-26 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
CA2948441A1
(en)
|
2014-05-12 |
2015-11-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions for treating infectious diseases
|
GB201512635D0
(en)
|
2015-07-17 |
2015-08-26 |
Ucl Business Plc |
Uses of therapeutic compounds
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
KR20200112900A
(ko)
|
2018-01-20 |
2020-10-05 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
치환된 아미노피리미딘 화합물 및 이의 사용 방법
|
CA3173172A1
(en)
|
2020-03-26 |
2021-09-30 |
Christopher D. Kane |
Cathepsin inhibitors for preventing or treating viral infections
|